Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis
Status:
Withdrawn
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether giving abciximab (ReoPro) to children with
sickle cell disease who are hospitalized for acute pain crisis will improve their pain and
shorten the time spent in the hospital, when compared with standard supportive care.